Publication | Open Access

Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma

VaccinationTumor ImmunologyCancer ImmunosurveillanceAllergyImmunologyTumor-lysate VaccineTherapeutic VaccineAutoimmunityImmunotherapeuticsImmunomodulationAggressive T-cell LymphomaImmunosuppressionImmune Cell TherapyImmunotherapyMedicineSystemic Administration